Australia's Cleo Diagnostics hits record high on positive study for cancer blood test

CLEO Diagnostics

29/05/2024 02:06

** Shares of Cleo Diagnostics  COV.AX  rise as much as 52.9%
to an all-time high of A$0.260
    ** Stock posts record intraday percentage gain
    ** The diagnostics co says a study has found its ovarian
cancer blood test outperforms current clinical workflows that
use CA125 and ultrasound to predict malignancy
    ** About 695,000 shares change hands, compared with the
30-day average volume of around 42,000
    ** Cleo stock down 2.9% YTD, based on last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))